![]() | |
![]() | |
Clinical data | |
---|---|
Other names | BU-LAD; BULAD; 6-Butyl-6-nor-LSD; 6-Butyl-6-nor-Lysergic acid diethylamide |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H31N3O |
Molar mass | 365.521 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
BU-LAD, also known as 6-butyl-6-nor-LSD or 6-butyl-6-nor-lysergic acid diethylamide, is an analogue of LSD first described by David E. Nichols and colleagues in the 1980s. [1] [2] According to Alexander Shulgin, BU-LAD is a psychedelic drug similar to LSD, but is significantly less potent than LSD, with a dose of 500 μg producing only mild effects. [3]
TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats [...]
Ergolines (incl. lysergines) |
|
---|---|
Clavines (6,8-dimethylergolines) | |
Lysergamides (lysergic acid amides) |
|
Ergopeptines (peptide ergolines) |
|
Partial ergolines |
|
Related compounds | |
Natural sources |
|
|
![]() | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |